Navigation Links
Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
Date:3/3/2008

Phase 2b Trial to Examine Safety and Efficacy of DARA versus Active Control

PRINCETON, N.J., March 3 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the initiation of a Phase 2b clinical study of PS433540, the company's lead internal product candidate. This randomized, double-blind, placebo and active-controlled, parallel-group study is designed to evaluate the compound's safety and efficacy at three different doses in subjects with Stage 1 and Stage 2 hypertension.

After a lead-in period, the multi-center trial is expected to randomize approximately 375 subjects into five study arms receiving PS433540 (200 mg, 400 mg or 800 mg); irbesartan (300 mg), an angiotensin II receptor antagonist; or placebo. All doses will be administered once daily for 12 weeks. The trial's primary objective is to compare the change from baseline in mean seated systolic blood pressure for each dose of PS433540 with placebo. Additional study objectives include comparisons of changes in blood pressure for each dose of PS433540 with irbesartan.

"We are pleased with the DARA program's rapid progress. This is our second Phase 2 study of PS433540 in hypertensive patients to provide key indications of the compound's therapeutic potential," said Les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "We look forward to the completion of this study by the end of 2008 as well as the reporting of results from our on-going Phase 2a trial in the second quarter of 2008."

Pharmacopeia recently completed enrollment in its ongoing Phase 2a trial of PS433540 in patients with Stage 1 and Stage 2 hypertension. Results from that study
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
2. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
3. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
4. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
5. Pharmacopeia Announces Third Quarter 2007 Financial Results
6. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
7. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
8. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: ... fiduciary duties to shareholders or violated the federal securities ... disclosed: "On September 11, 2014, [PDL] was orally notified ... LLP ("EY"), that it was resigning effective September 11, ...
(Date:9/19/2014)... /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... report firstly reviews the basic information of ... manufacturing technology. The report then explores global ... listing their product specification, capacity, Production value, ...
(Date:9/19/2014)... CHICAGO, Ill. , Sept. 19, 2014  The ... ABBV ) declared a quarterly cash dividend of $0.42 ... payable Nov. 17, 2014 to stockholders of record at ... About AbbVie AbbVie is a global, research-based biopharmaceutical ... company,s mission is to use its expertise, dedicated people ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5
... of Orange Park is hosting a car wash to raise money ... AM at the Hooters of Orange Park located at 1740 Wells ... from the car wash will go toward the Kelly Jo Dowd ... the country is raising money through various charitable efforts in the ...
... Reinforce March of Dimes Message: Start Taking a Vitamin ... Women who take folic acid supplements for at ... their risk of having a premature baby by half, ... journal, PLOS Medicine.The study links pre-conceptional folate supplementation of ...
Cached Medicine Technology:Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2
(Date:9/20/2014)... The Arizona Advanced Manufacturing ... National Manufacturing Day by opening its doors to the ... additive manufacturing labs will be offered between 10 a.m. ... Southern and Dobson campus (1833 W. Southern Ave, Mesa, ... , The AzAMI at MCC was established in the ...
(Date:9/20/2014)... “Motherhood is a wonderful gift and a huge responsibility,” ... article , “We know that you want to care for ... want to do as well.” , The article explains to ... their Family Physicians who practice obstetrics while pregnant, during delivery, ... To learn more about Community Health Center of Snohomish County ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 The children ... the balanced and active play they need. An empty ... Center - Lakeview Campus was transformed into a kid-designed ... of 150+ volunteers from Branches (@BranchesFL), ESPN (@TeamESPN), Disney ... , KaBOOM! believes a playground is more than a ...
(Date:9/19/2014)... York, NY (PRWEB) September 20, 2014 ... moderate revenue growth for the Vision Insurance industry ... pace, to the detriment of industry margins. From ... noticeably increase. Industry operators provide coverage for routine ... discounted pricing for eyeglasses, contact lens and refractive ...
(Date:9/19/2014)... 19, 2014 Are you tired of ... problems with seasonal allergies or sinus congestion? Fortunately, an ... alternative. , She conceived of Nose Pal to ... runny nose in public. Since it prevents nasal drip ... sanitary conditions, particularly when cooking or working closely with ...
Breaking Medicine News(10 mins):Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 3Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 4Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2
... with Autism is the focus of the research of one ... Economic and Social Research Council (ESRC) and the Young Foundation. ... the causes of autism rather than understanding it as a ... over a period of three years Dr Elizabeth Pellicano, from ...
... Lady Laura Bush,today saluted the U.S. Department of ... Prevention Initiative, announced today at,the National Prevention Summit, ... weight for children., Mrs. Bush delivered the ... event that highlights new approaches to prevention,and health ...
... Ventas, Inc. (NYSE:,VTR) ("Ventas" or the "Company") said ... dividend of $0.475 per share, payable in cash,on December ... 2007. The,dividend is the fourth quarterly installment of the ... quarterly installment of the Company,s 2007 annual dividend,will be ...
... bizarre behaviors and sudden deaths , , TUESDAY, Nov. ... Drug Administration advisory panel recommended Tuesday that the prescription ... label to reflect reports of bizarre behaviors and deaths ... a 9-5 vote, said that drug maker Roche Holding ...
... SAN DIEGO, Nov. 27 Gen-Probe Incorporated,(Nasdaq: GPRO ... the NASDAQ,20th Investor Program in London on Thursday, December ... a.m. Eastern Time). The,presentation is scheduled to be webcast ... investor information section of Gen-Probe,s website at, http://www.gen-probe.com . ...
... Address Growing Healthcare Trends and the Tools Health Plans ... ... Portico Systems, the leader in,Provider Network Management solutions, will host a ... practices for,provider network management. The complimentary series starts Tuesday,December 4th, showcasing ...
Cached Medicine News:Health News:Autism focus of prize winning research 2Health News:HHS Launches Childhood Overweight and Obesity Prevention Initiative 2Health News:HHS Launches Childhood Overweight and Obesity Prevention Initiative 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 4Health News:FDA Panel Backs Stronger Warning for Tamiflu 2Health News:FDA Panel Backs Stronger Warning for Tamiflu 3Health News:Gen-Probe to Webcast Presentation at NASDAQ 20th Investor Program 2Health News:Portico Systems Offers Webinar Series to Share Provider Network Management Best Practices 2
30 Degree Angle Shaft with 1.0mm 90 Degree Angle Tip; in stainless steel....
0.5mm "K" hook. Rounded knurled handle; shaft angled 11mm from tip; overall length 120mm, in Titanium....
Lightly Curved-Blunt Tips Rounded Blades; 1mm Eye in Blades; 27mm from mid screw to tip. Matte finish; Stainless Steel, overall length 120mm...
... Catheter is indicated for balloon ... of a coronary artery or ... purpose of improving myocardial perfusion. ... also designed to provide distal ...
Medicine Products: